Press Releases

Date Title and Summary Additional Formats
Toggle Summary Concert Pharmaceuticals to Present at the 30th Annual Cowen and Company Health Care Conference on Monday, March 8
Concert Pharmaceuticals to Present at the 30th Annual Cowen and Company Health Care Conference on Monday, March 8 Lexington, Mass -- Concert Pharmaceuticals, Inc. announced today that it will be presenting at the Cowen and Company 30th Annual Health Care Conference, being held March 8-11, 2010 at
View HTML
Toggle Summary Concert Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference on Monday, January 11
Concert Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference on Monday, January 11 Lexington, MA -- Concert Pharmaceuticals, Inc. announced today that it will be presenting at the 28th Annual J.P. Morgan Healthcare Conference, being held at the Westin St.
View HTML
Toggle Summary Concert Pharmaceuticals Initiates Phase 1b Clinical Trial of CTP-518, Protease Inhibitor for Treatment of HIV
Concert Earns $12 Million Milestone from GlaxoSmithKline CTP-518 has Potential as Unboosted HIV Protease Inhibitor
View HTML
Toggle Summary Concert Pharmaceuticals to Participate on a Private Company Panel at the Merriman Curhan Ford 6th Annual Investor Summit
Concert Pharmaceuticals to Participate on a Private Company Panel at the Merriman Curhan Ford 6th Annual Investor Summit Lexington, MA -- Concert Pharmaceuticals, Inc. announced today that Roger Tung, Ph.D., President and Chief Executive Officer of Concert, will participate on the Healthcare
View HTML
Toggle Summary Concert Pharmaceuticals’ Roger Tung Awarded 2009 Mass High Tech All Star Award
Concert Pharmaceuticals’ Roger Tung Awarded 2009 Mass High Tech All Star Award Lexington, MA -- Concert Pharmaceuticals, Inc. announced today that Roger Tung, Ph.D., President and Chief Executive Officer, has been named a 2009 Mass High Tech All Star for his contributions to the pharmaceutical
View HTML
Toggle Summary Concert Pharmaceuticals to Present at Second Annual Boston Biotech R&D Conference
Concert Pharmaceuticals to Present at Second Annual Boston Biotech R&D Conference Lexington, MA -- Concert Pharmaceuticals, Inc. today announced that it will be presenting at the 2009 Boston Biotech R&D Conference being held at Harvard Medical School in Boston, Massachusetts.  Roger Tung, Ph.D.,
View HTML
Toggle Summary Concert Pharmaceuticals Selected by AlwaysOn as an OnDC Top 100 Winner; Recognized for Innovative Technology for Game-Changing New Medicines
Concert Pharmaceuticals Selected by AlwaysOn as an OnDC Top 100 Winner; Recognized for Innovative Technology for Game-Changing New Medicines Lexington, MA -- Concert Pharmaceuticals, Inc. today announced that it has been chosen by AlwaysOn as one of the OnDC Top 100 Winners.  Inclusion in the OnDC
View HTML
Toggle Summary Concert Pharmaceuticals Presents Clinical Results Demonstrating Reduced Drug-Drug Interactions with a Deuterium-Modified Compound; Phase I Results Presented at American College of Clinical Pharmacology
Concert Pharmaceuticals Presents Clinical Results Demonstrating Reduced Drug-Drug Interactions with a Deuterium-Modified Compound; Phase I Results Presented at American College of Clinical Pharmacology San Antonio, TX -- Concert Pharmaceuticals, Inc. announced today the presentation of Phase 1 data
View HTML
Toggle Summary Concert Pharmaceuticals to Present at the Thomas Weisel Partners 2009 Healthcare Conference on September 10, 2009
Concert Pharmaceuticals to Present at the Thomas Weisel Partners 2009 Healthcare Conference on September 10, 2009 LEXINGTON, Mass -- Concert Pharmaceuticals, Inc. announced today that Roger Tung, Ph.D., President and Chief Executive Officer of Concert, will present at the Thomas Weisel Partners
View HTML
Toggle Summary Concert Pharmaceuticals and GlaxoSmithKline Form Alliance to Develop Novel Deuterium Modified Drugs
Concert Pharmaceuticals and GlaxoSmithKline Form Alliance to Develop Novel Deuterium Modified Drugs Concert Pharmaceuticals and GlaxoSmithKline Form Alliance to Develop Novel Deuterium Modified Drugs LEXINGTON, Mass and London -- Concert Pharmaceuticals and GlaxoSmithKline (NYSE: GSK) announced
View HTML